Employers and health plans are concerned about managing high-ticket items such as cell and gene therapies, and interested in potential savings from biosimilars, according to a large managed care survey presented at Asembia’s AXS24 Summit, in Las Vegas.
The survey, detailed in the Trends in Specialty Drug Benefits Report by the Pharmaceutical Strategies Group (PSG), sampled 185 benefits leaders representing employers, health plans and unions/Taft-Hartley plans covering an